Entries Tagged as ''

FDA Safety Changes: Levitra, Minocin, Zyvox

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis.

August 8, 2007 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of drug interactions with vardenafil and the additive effect on QT interval prolongation associated with concomitant use of certain medications, and the potential for development of Clostridium difficile-associated diarrhea more than 2 months after completion of therapy with minocycline HCl or linezolid. [Read more →]

Tags: Levitra news by admin
No Comments »

European officials have approved a once-daily version of impotence pill Cialis

European officials have approved a once-daily version of impotence pill Cialis.

The drug’s maker, Eli Lilly and Co., said on Monday that the green light from the European Commission meant Cialis was the first erectile dysfunction medicine cleared for continuous use.

Until now, drugs such as Cialis and Pfizer Inc.’s rival product, Viagra, have been taken as needed. The new low-dose formulation of Cialis, by contrast, is taken all the time, which eliminates the need to plan sex within a limited timeframe. It is aimed at men who anticipate sexual activity at least twice a week.

Lilly plans to start launching the once-daily version in certain European countries in the second half of 2007.

Tags: Cialis news by admin
2 Comments »